Highlights Jaguar Health, Inc.

Equities

JAGX

US47010C7065

Real-time Estimate Cboe BZX Other stock markets 03:52:59 2024-05-06 pm EDT			5-day change	1st Jan Change
0.316 ^USD	-0.63%		+52.74%	+109.84%

03:09pm	Jaguar Health Applies for Investigational New Animal Drug Status for Potential Dog Diarrhea Treatment	MT
Apr. 19	Venture Life renews revolving credit facility with Santander and HSBC	AN

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Venture Life renews revolving credit facility with Santander and HSBC	Apr. 19	AN
Wall Street Set to Open Sharply Lower Wednesday as Inflation Rises More Than Expected	Apr. 10	MT
Exchange-Traded Funds Down, Equity Futures Higher Pre-Bell Wednesday Ahead of Fed Meeting Minutes	Apr. 10	MT
Top Premarket Gainers	Apr. 10	MT
Jaguar Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Jaguar Health Reaches Agreement With FDA on Design, Conduct of Medicine Study	Feb. 15	MT
Jaguar Health, Inc. Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea in Dogs	Feb. 15	CI
Napo Pharmaceuticals, Inc. Announces Majority of Subjects in Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Continue on to Stage II	Dec. 11	CI
FDA Approves Renewal of Canalevia-CA1, Jaguar Health?s Drug for Chemotherapy-Induced Diarrhea in Dogs	Dec. 04	CI
Jaguar Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Jaguar Health Gets Additional 180-Day Grace Period to Regain Nasdaq Compliance	Nov. 08	MT
Jaguar Health, Inc. Announces Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome	Nov. 01	CI
Earnings Flash (JAGX) JAGUAR HEALTH Reports Q2 Revenue $2.7M	23-08-14	MT
Jaguar Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Jaguar Health, Inc. Announces the Results of an Independent Pilot Phase 2 Study of Crofelemer for the Management ofneratinib-Associated Diarrhea	23-08-07	CI
Jaguar Health Says FDA Activates Third-Party Investigational New Drug Application for Crofelemer	23-08-01	MT
Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome	23-08-01	CI
Jaguar Health Unit Submits Investigational New Drug Application to FDA for Therapy to Treat Microvillus Inclusion Disease	23-06-28	MT
Napo Pharmaceuticals Submits Investigational New Drug Application to FDA for MicroVillus Inclusion Disease	23-06-28	CI
Earnings Flash (JAGX) JAGUAR HEALTH Posts Q1 Revenue $2M	23-05-15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Jaguar Health, Inc.

Equities

JAGX

US47010C7065

Highlights

Filters